ADVERTISEMENT
Award-Winning Science Uses Routine CCTA to Predict Cardiac Death, Heart Attack Risk
ARLINGTON, VA — The Society of Cardiovascular Computed Tomography (SCCT) honors Kenneth Chan, MBBS as recipient of the 2024 SCCT Clinical Trials and Registries Award (CTRA), supported by Cleerly.
The award recognizes clinical trials that use computed tomography coronary angiography (CCTA) and/or CCTA-based analyses to detect atherosclerotic burden in the diagnosis and treatment of coronary artery disease, as well as demonstrate a positive impact on patient outcomes.
Dr. Chan’s winning submission, “Socioeconomic disparities and the prognostic value of coronary inflammatory risk from routine coronary CT angiography: The Oxford Risk Factors and Non-Invasive Imaging (ORFAN) study,” investigates the relationship between coronary inflammation and social deprivation status, which is considered a driver for cardiovascular disease.
James K. Min, MD, MSCCT, founder and CEO of Cleerly, said, "We applaud Dr. Kenneth Chan for winning first place for his robust study design and its broad applicability of using routine CT angiography to observe inflammation in coronary arteries in relation to socioeconomic disparities. Through our support of this award, we aim to recognize and acknowledge the impactful contributions in cardiovascular care through innovative research and we commend Dr. Chan’s dedication to advancing both knowledge and equality with his work.”
The study evaluated the ability of the Fat Attenuation Index (FAI) Score on routine CCTA to predict cardiovascular outcomes in different socioeconomic classes, ethnicity groups, and in the presence or absence of obstructive coronary artery disease (CAD).
Dr. Chan is a clinical research fellow in the Division of Cardiovascular Medicine at University of Oxford in the United Kingdom.
SCCT and Cleerly will present Dr. Chan with the award at the opening session of the Society’s 19th Annual Scientific Meeting (SCCT2024) on Friday, July 19 at the Marriott Marquis in Washington, DC, followed by a presentation of his study.
“SCCT offers our heartfelt congratulations to Dr. Chan for his exemplary work as first author of the ORFAN study, a submission which stood out for its strong study design and methodology, as well as its broad applicability,” said ASM Program Committee Chair and incoming President Maros Ferencik, MD, PhD, MCR, MSCCT. “His trial demonstrated that the most socioeconomically deprived population remained at significantly higher risk of cardiac death and non-fatal heart attacks and the risk was mediated by coronary inflammation detected on cardiovascular CT scans. This information can help practitioners close the gap in patient outcomes for low socioeconomic status groups. We’re thrilled to recognize the profound impact his research will have on the diagnosis and management of cardiovascular disease and look forward to his presentation in July.
The judging panel named Márton Kolossváry, MD, PhD as runner-up for his submission, “Pitavastatin reduces noncalcified coronary artery plaque via pro-collagen PCOLCE, independently of LDL lowering: An analysis of the REPRIEVE mechanistic substudy.”
Dr. Kolossváry is head of the Department of Clinical Research at Semmelweis University in Budapest, Hungary. He will present his study and receive this award at the SCCT2024 Best Original Science session at 10:30 am ET on Saturday, July 20.
In addition to the spotlighted presentation, the CTRA comes with a $10,000 prize; one year of membership in SCCT; complimentary Annual Meeting registration; travel support to Washington, DC; accommodation at the Marriott Marquis Hotel and a plaque.
###
About the Society of Cardiovascular Computed Tomography
Founded in 2005, the Society of Cardiovascular Computed Tomography (SCCT) is the international professional society devoted to improving health outcomes through effective use of cardiovascular computed tomography (CCT), with members from over 85 countries. SCCT is a community of physicians, scientists and technologists advocating for access, research, education and clinical excellence in the use of CCT. For more information, please visit https://scct.org.
About Cleerly
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Cleerly’s approach is grounded in science, based on over 10 million images from over 40,000 patients gathered over a 15-year-period in landmark, multicenter clinical trials. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit https://cleerlyhealth.com.
Find More:
The Latest Clinical & Industry News
Grand Rounds With Morton Kern, MD
Podcasts: Cath Lab Conversations
Go to Cath Lab Digest's current issue page
About the 19th Annual Scientific Meeting of SCCT (SCCT2024)
SCCT2024 – the preeminent meeting focused on cardiovascular CT – will be held July 18 - 21, 2024 in Washington, DC. The SCCT Annual Scientific Meeting is designed to engage physicians, trainees, technologists and healthcare professionals in a complete overview of the cardiovascular CT field. Planned sessions are targeted for all levels, from new practitioners to experienced providers. Sessions range from general overviews to state-of-the-art research and expert discussions. For more information, please visit https://scct.org/SCCT2024.
